Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OGEN

Oragenics Inc

Sep 20 • 04:00PM ET

0.4800

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.20	Insider Own	13.12%	Shs Outstand	8.66M	Perf Week	-9.30%
Market Cap	4.16M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	7.52M	Perf Month	-49.15%
Income	-19.52M	PEG	-	EPS next Q	-	Inst Own	8.51%	Short Float	17.56%	Perf Quarter	-66.67%
Sales	0.01M	P/S	415.68	EPS this Y	-	Inst Trans	12.90%	Short Ratio	1.88	Perf Half Y	-67.35%
Book/sh	-0.05	P/B	-	EPS next Y	-	ROA	-349.31%	Short Interest	1.32M	Perf Year	-84.00%
Cash/sh	0.16	P/C	3.08	EPS next 5Y	-	ROE	-454.72%	52W Range	0.47 - 7.74	Perf YTD	-91.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.34%	ROI	-1471.37%	52W High	-93.80%	Beta	0.49
Dividend TTM	-	Quick Ratio	1.17	Sales past 5Y	-20.00%	Gross Margin	35.91%	52W Low	2.13%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	1.17	EPS Y/Y TTM	-6.81%	Oper. Margin	-125681.32%	RSI (14)	35.73	Volatility	9.30% 12.01%
Employees	5	Debt/Eq	0.00	Sales Y/Y TTM	-93.58%	Profit Margin	-261401.51%	Recom	1.00	Target Price	90.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	66.22%	Payout	-	Rel Volume	0.25	Prev Close	0.48
Sales Surprise	-	EPS Surprise	40.00%	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	703.09K	Price	0.48
SMA20	-35.58%	SMA50	-51.80%	SMA200	-78.51%	Trades		Volume	178,069	Change	0.00%

Sep-05-24 04:30PM	Oragenics, Inc. Announces Closing of Public Offering (GlobeNewswire) -8.81%
Sep-04-24 08:36AM	Oragenics, Inc. Announces Pricing of Public Offering (GlobeNewswire) -46.20%
Aug-21-24 08:45AM	Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients (GlobeNewswire)
Aug-16-24 04:30PM	Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) -21.53% -9.73%
Aug-14-24 08:30AM	Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range (GlobeNewswire) -19.28%
08:30AM	Loading…
Aug-12-24 08:30AM	Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study (GlobeNewswire) +48.57%
Aug-09-24 04:43PM	Oragenics: Q2 Earnings Snapshot (Associated Press Finance) +29.63%
09:00AM	As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032 (PR Newswire)
Aug-08-24 08:45AM	Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing (GlobeNewswire) +11.74%
08:30AM	EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway (Benzinga)
Jul-10-24 08:00AM	Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients (GlobeNewswire) +11.32%
Jun-27-24 08:30AM	Oragenics Develops Automated Intranasal Device for Treating Concussed Patients (GlobeNewswire)
Jun-26-24 04:47PM	Oragenics, Inc. Announces Closing of Public Offering (GlobeNewswire)
Jun-25-24 08:30AM	Oragenics, Inc. Announces Pricing of Public Offering (GlobeNewswire) -23.37%
Jun-24-24 06:43PM	Oragenics, Inc. Announces Proposed Public Offering (GlobeNewswire) -9.38%
08:00AM	Loading…
Jun-20-24 08:00AM	Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance (GlobeNewswire) -5.23%
May-22-24 08:00AM	Oragenics Appoints William Frank Peacock MD as Chief Clinical Officer (GlobeNewswire) -17.43%
May-17-24 08:00AM	Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine (GlobeNewswire) +42.07%
May-16-24 12:52PM	Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise (MT Newswires)
08:00AM	Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial (GlobeNewswire)
May-15-24 01:07PM	Oragenics: Q1 Earnings Snapshot (Associated Press Finance)
May-07-24 08:00AM	Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia (GlobeNewswire) +24.07%
Apr-19-24 05:50PM	Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards (Business Wire) -6.19%
Apr-01-24 09:05AM	Oragenics, Inc. Files 10K and Provides Company Update (Business Wire)
Mar-18-24 07:00AM	Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion (Business Wire)
Mar-17-24 08:38AM	15 Highest Quality Probiotics For Gut Health (Insider Monkey)
Mar-05-24 07:45AM	Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion (Business Wire)
Mar-01-24 04:04PM	Oragenics Announces Closing of Public Offering (Business Wire)
Feb-27-24 09:25PM	Oragenics Announces Pricing of Public Offering (Business Wire) -22.47% -42.04%
04:33PM	Oragenics Announces Proposed Public Offering (Business Wire)
04:41PM	Loading…
Feb-12-24 04:41PM	Oragenics, Inc. Announces Leadership Transition (Business Wire) -5.54% -11.47%
Feb-07-24 08:00AM	Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement (Business Wire) +24.08%
Feb-05-24 08:00AM	Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion (Business Wire) -6.06%
Jan-23-24 05:34PM	Oragenics Announces Termination of At-The-Market Offering Program (Business Wire)
Jan-02-24 07:30AM	Oragenics Completes Acquisition of Odyssey Healths Neurological Assets (Business Wire) +20.51%
Nov-10-23 09:19AM	Oragenics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-02-23 07:00AM	Oragenics Issues Update to Shareholders (Business Wire)
Oct-18-23 08:30AM	Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors (Business Wire)
08:30AM	Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc. (ACCESSWIRE)
Oct-05-23 06:30AM	Oragenics to Acquire Odyssey Healths Neurological Drug Technology Pipeline Including Concussion Drug Candidate (Business Wire) +13.00%
Sep-29-23 04:00PM	Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets (Business Wire)
Aug-14-23 02:46PM	Oragenics: Q2 Earnings Snapshot (Associated Press Finance)
Aug-07-23 08:30AM	Oragenics, Inc. Announces Private Placement (Business Wire)
Jun-05-23 04:18PM	Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM (Business Wire)
May-12-23 06:32PM	Oragenics: Q1 Earnings Snapshot (AP Finance)
Mar-29-23 11:45AM	Oragenics to Participate in the World Vaccine Congress Washington (Business Wire)
Mar-14-23 08:30AM	Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE (Business Wire)
Mar-08-23 09:09AM	Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team (Business Wire)
Mar-01-23 01:47PM	Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact (Benzinga)
07:30AM	Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate (Business Wire)
Feb-03-23 07:30AM	Oragenics, Inc. Regains Compliance with NYSE American (Business Wire) +5.12%
Jan-30-23 02:24PM	7 Short-Squeeze Stocks to Buy Before They Soar (InvestorPlace) +7.58%
Dec-23-22 04:05PM	Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split (Business Wire) -6.69% -13.72%
Dec-22-22 07:30AM	Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate (Business Wire) +17.73%
Dec-20-22 04:36PM	Oragenics, Inc. Receives NYSE American Notice (Business Wire) -19.22%
Dec-19-22 04:34PM	Oragenics, Inc. Announces New Chair (Business Wire)
Oct-24-22 04:01PM	Oragenics to Participate in the 2022 BioFlorida Annual Conference (Business Wire)
Sep-30-22 07:30AM	Oragenics Issues Letter to Shareholders (Business Wire)
Aug-24-22 07:00AM	Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate (Business Wire) -5.48%
Jun-23-22 04:30PM	Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer (Business Wire) +8.47%
Jun-14-22 07:30AM	Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports (Business Wire)
May-17-22 07:30AM	Oragenics Issues Letter to Shareholders (Business Wire)
May-13-22 04:17PM	Here's why meme stocks are hinting at another flashy rally for `junk stocks` (Yahoo Finance) +12.84%
Apr-18-22 07:30AM	Oragenics to Participate at the World Vaccine Congress Washington 2022 (Business Wire)
Apr-06-22 07:30AM	Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses (Business Wire)
Mar-25-22 07:30AM	Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation (Business Wire) -10.46%
Mar-22-22 08:59AM	Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1 (Business Wire)
Mar-10-22 07:30AM	Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1 (Business Wire)
Mar-03-22 09:09AM	Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript (Business Wire)
Feb-07-22 01:45PM	5 Stocks Insiders Are Buying Amid a Tech Stocks Rout (InvestorPlace)
Jan-26-22 07:30AM	Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (Business Wire)
Jan-14-22 05:38PM	Sara-Bay Financial Buys Cerence Inc, Public Service Enterprise Group Inc, Welltower Inc, Sells ... (GuruFocus.com)
Jan-04-22 12:02PM	OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph Today (InvestorPlace) +18.44%
Dec-20-21 12:08PM	Oragenics Extends Collaboration with NRC Canada For Omicron-Specific Vaccine (Benzinga) +7.27%
08:00AM	Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant (Business Wire)
Dec-09-21 08:00AM	Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners (Business Wire)
Dec-08-21 08:00AM	Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics (Business Wire)
Dec-01-21 08:00AM	Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate (Business Wire) -9.48%
Nov-23-21 08:30AM	Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (Business Wire) -7.77%
Oct-04-21 07:30AM	Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics. (Business Wire)
Sep-15-21 11:01AM	Oragenics Launches Animal Study For COVID-19 Vaccine Candidate (Benzinga)
07:30AM	Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate (Business Wire)
Aug-31-21 09:15AM	Company News for Aug 31, 2021 (Zacks)
Aug-30-21 10:06AM	Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development (Benzinga)
07:30AM	Oragenics SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants (Business Wire)
Aug-24-21 07:30AM	Oragenics Announces Postponement of Annual Meeting of Shareholders (Business Wire)
Jul-27-21 07:00AM	Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines (Business Wire) +34.14%
Jul-12-21 10:10AM	10 Popular Penny Stocks on Robinhood (Insider Monkey)
Jul-01-21 07:00AM	Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (Business Wire)
May-18-21 07:30AM	Oragenics Issues Letter to Shareholders (Business Wire) +11.53%
May-03-21 07:30AM	Oragenics Announce Changes in Management and Board of Directors (Business Wire) -9.00%
Apr-09-21 10:50AM	OGEN: COVID-19 Vaccine Candidate Exhibits Protective Immunity in Mice (Zacks Small Cap Research)
Mar-09-21 12:09PM	Oragenics' COVID-19 Related Deal Pushes The Stock Higher (Benzinga) +47.97%
07:00AM	Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine (Business Wire)
Mar-08-21 07:30AM	Oragenics to Participate in Two Investment Conferences During March (Business Wire)
Feb-12-21 08:00AM	Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock (Business Wire)
Feb-02-21 08:00AM	SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice (Business Wire)
Jan-14-21 07:00AM	Oragenics Issues Letter to Stockholders (Business Wire) +23.63%
Jan-07-21 07:00AM	Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant (Business Wire) +35.48%
Dec-29-20 04:00PM	Oragenics Announces Closing of $6.5 Million Registered Direct Offering (Business Wire)

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Telling Fred	Director	Nov 30 '23	Sale	3.57	3,500	12,488	38,345	Dec 01 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OGEN

Oragenics Inc

Upgrade your FINVIZ experience